Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Etofenamate is a nonsteroidal anti-inflammatory drug (NSAID) of the flufenamic acid derivative group used primarily for the topical treatment of joint and muscular pain. It is available as a cream, gel, or spray for local application and can also be administered intramuscularly in some settings. Etofenamate exerts its effects by inhibiting both cyclooxygenase (COX) and lipoxygenase enzymes, thereby reducing prostaglandin and leukotriene synthesis. This dual inhibition results in analgesic and anti-inflammatory properties. Additionally, etofenamate inhibits other inflammatory mediators such as histamine release, bradykinin antagonism, serotonin antagonism, complement system activity inhibition, and hyaluronidase inhibition[5][6][7]. It is indicated for localized painful conditions of the musculoskeletal system including arthropathies (joint diseases), myalgias (muscle pain), bursitis (inflammation of fluid-filled sacs around joints), neuralgia (nerve pain), contusions (bruises), strains or sprains[5]. Due to poor oral bioavailability it is not administered orally[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on etofenamate.